Rovaldi Christopher
SEC CIK 1706040 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | COO | 60.0K | — | $162.0K | 5 | 2022-04-01 | 2025-02-18 |
Most active insiders at KROS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneeberger Daniel | 10% | — | $95.66M |
| 2 | Pontifax (China) IV L.P. | 10% | — | $84.98M |
| 3 | Cho Esther | SVP, GC | — | $123.7K |
| 4 | Seehra Jasbir | CEO, Dir | — | $113.4K |
| 5 | Lerner Lorena Raquel | CSO | — | $100.0K |
| 6 | Regnante Keith | CFO | — | $77.5K |
| 7 | BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| 8 | Knowles Julius | Dir | — | $28.2K |
| 9 | Farzan Nima | Dir | — | $28.2K |
| 10 | Seth Alpna | Dir | — | $28.1K |
Rovaldi Christopher made no open-market trades at KROS in the last 12 months.
Transactions 5
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-19 | 2025-02-18 | KROS | Keros Therapeutics, Inc. | Rovaldi Christopher | COO | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 | |
| D | 2022-04-08 | 2022-04-06 | KROS | Keros Therapeutics, Inc. | Rovaldi Christopher | COO | S - Sale+OE | $65.00 | -1,728 | 0 | -100% | -$112.3K |
| D | 2022-04-08 | 2022-04-06 | KROS | Keros Therapeutics, Inc. | Rovaldi Christopher | COO | M - OptEx | $16.00 | +1,728 | 1,728 | New | +$27.6K |
| DM | 2022-04-05 | 2022-04-01 | KROS | Keros Therapeutics, Inc. | Rovaldi Christopher | COO | S - Sale+OE | $57.49 | -864 | 0 | -100% | -$49.7K |
| D | 2022-04-05 | 2022-04-01 | KROS | Keros Therapeutics, Inc. | Rovaldi Christopher | COO | M - OptEx | $16.00 | +864 | 864 | New | +$13.8K |
Purchase Sale Sale after option exercise All abbreviations